Archeus Fortifies Board, Signaling Major Push in Radiopharma Race

MADISON, WI – August 04, 2026 – In a calculated move signaling a new phase of aggressive growth, clinical-stage biotech firm Archeus Technologies has reconstituted its advisory board, assembling a roster of world-renowned experts in oncology and drug development. This strategic overhaul is seen by market watchers as a clear bid to accelerate its promising pipeline of radiopharmaceutical therapies (RPTs) and solidify its position in one of healthcare's most competitive and rapidly expanding frontiers.

The announcement goes beyond a typical leadership shuffle. By handpicking advisors whose expertise directly maps to its clinical and preclinical assets, Archeus is building a formidable strategic framework aimed at navigating the complex journey from laboratory science to market-ready cancer treatments.

A Strategic Infusion of Expertise

The reconstituted board is a significant upgrade in the caliber of guidance available to the company as it pushes two programs through Phase 1 trials. The new members bring a wealth of experience that aligns precisely with the scientific and commercial challenges ahead.

“The Advisory Board has been rebuilt to reflect where Archeus is today — a company with two active Phase 1 programs and a pipeline of novel assets behind them,” said Dr. Norman LaFrance, chair of Archeus’ Advisory Board, in a statement. He emphasized that the new advisors were selected because their expertise “maps directly to the decisions Archeus is making now.”

Among the new appointees is Dr. Jeremie Calais of UCLA, a leading authority in PSMA theranostics. His deep knowledge of prostate-specific membrane antigen (PSMA) imaging and radionuclide therapy is particularly relevant to Archeus’s ART-101 program, a novel PSMA-targeting agent for prostate cancer. Dr. Calais was instrumental in the academic NDA submission that led to the first FDA-approved PSMA PET imaging agent, giving him unparalleled insight into the regulatory and clinical pathways for such therapies.

Also joining is Dr. Lawrence Fong from the Fred Hutch Cancer Center, a physician-scientist who has been a central figure in the development of FDA-approved immunotherapies. His expertise is critical for Archeus's ARC-706 program, which is being trialed in combination with immune checkpoint inhibitors (ICIs). Dr. Fong’s experience in leading clinical trials that combine RPTs with immunotherapies provides Archeus with invaluable guidance on how to maximize the synergistic potential of these powerful treatment modalities.

Rounding out the heavyweight trio is Dr. Stuart Grossman from the Johns Hopkins Kimmel Cancer Center. With over two decades leading National Cancer Institute-funded brain tumor consortia, Dr. Grossman is a master of designing and managing large, multi-center clinical trials. As Archeus looks to expand its clinical footprint, his experience in scaling early-phase studies will be indispensable.

“This board reflects the company we are becoming,” said Dr. Evan Sengbusch, president and CEO of Archeus Technologies. “We are moving into a more demanding phase of development, and we’re building the leadership around us to match that ambition.”

Advancing a Precision Pipeline

The bolstered advisory board will oversee a pipeline focused on small-molecule RPTs, which are designed to deliver potent radiation directly to cancer cells while minimizing damage to healthy tissue. This "smart bomb" approach is at the heart of the company's two lead programs.

The first, a combination of ARC-706 and its companion diagnostic ARC-166, entered a Phase 1 trial in May 2026. The therapy is designed to enhance the effectiveness of immune checkpoint inhibitors in patients with metastatic cancer. By using a diagnostic to measure and guide the therapeutic dose, Archeus is embracing a core tenet of the theranostics revolution: see what you treat, and treat what you see. The FDA granted clearance for its Investigational New Drug (IND) application in late 2024, a key validation milestone.

The company's second clinical asset, ART-101, is a next-generation PSMA-targeting agent for metastatic castration-resistant prostate cancer (mCRPC). Following its IND clearance in mid-2025, ART-101 began its Phase 1 trial. Preclinical data suggests it could offer significant advantages over existing FDA-approved PSMA agents, including higher tumor uptake and lower toxicity in healthy tissues like salivary glands—a common and debilitating side effect of current therapies. Its compatibility with powerful alpha-emitting isotopes like actinium-225 could further enhance its therapeutic punch.

Navigating a High-Growth, High-Stakes Market

Archeus's strategic maneuvering comes as the radiopharmaceutical market is experiencing explosive growth and intense investor interest. Valued at over $17 billion in 2024, the market is projected by analysts to surge past $31 billion by the end of the decade. This boom is fueled by the clinical and commercial success of therapies like Novartis's Lutathera and Pluvicto, which have validated the RPT approach and paved the way for a new wave of innovation.

This validation has also triggered a consolidation frenzy, with major pharmaceutical giants aggressively acquiring promising radiopharma assets. Bristol Myers Squibb’s multi-billion dollar acquisition of RayzeBio and Novartis’s recent purchase of Mariana Oncology underscore the high strategic value placed on this therapeutic modality. For institutional investors, this environment creates a landscape ripe with opportunity, where a company with a differentiated pipeline and a clear strategic vision—like Archeus—can represent a significant value proposition, either as a standalone entity or a future acquisition target.

By strengthening its advisory board, Archeus is not just enhancing its scientific capabilities; it is sending a strong signal to the market that it is preparing to compete at the highest level.

The Wisconsin Connection: A Unique R&D Engine

Underpinning Archeus's strategy is its unique and deeply integrated relationship with the University of Wisconsin–Madison, a global powerhouse in radiopharmaceutical research. This is far more than a typical academic collaboration. The company enjoys what it calls "privileged access" to the university's world-class radiochemistry, imaging, and dosimetry facilities.

This symbiotic relationship is embodied by the company's own leadership. Archeus's Chief Technology Officer, Dr. Reinier Hernandez, is also an assistant professor at UW–Madison, and his lab is where the ART-101 asset was born. Similarly, Chief Medical Officer Dr. Zachary Morris co-directs a key theranostics initiative at the UW Carbone Cancer Center and is a co-chair of the ARC-706 study.

This seamless flow of talent, intellectual property, and resources from a leading academic institution provides Archeus with a sustainable R&D engine that is difficult for competitors to replicate. It de-risks development and accelerates the translation of cutting-edge science from the university lab bench to the company's clinical pipeline, a crucial advantage in the fast-paced race to develop the next generation of cancer therapies.